Phase 1
๐ Investigational Drug / Biologic
NCT06724016
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
๐ Massachusetts General Hospital โ Boston, Massachusetts
View Study & Screener โ